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Abstract
AIM
To define good and poor regression using pathology 
and magnetic resonance imaging (MRI) regression 
scales after neo-adjuvant chemotherapy for rectal 
cancer.
METHODS
A systematic review was performed on all studies 
up to December 2015, without language restriction, 
that were identif ied from MEDLINE, Cochrane 
Controlled Trials Register (1960-2015), and EMBASE 
(1991-2015). Searches were performed of article 
bibliographies and conference abstracts. MeSH and text 
words used included “tumour regression”, “mrTRG”, 
“poor response” and “colorectal cancers”. Clinical 
studies using either MRI or histopathological tumour 
regression grade (TRG) scales to define good and poor 
responders were included in relation to outcomes [local 
recurrence (LR), distant recurrence (DR), disease-free 
survival (DFS), and overall survival (OS)]. There was 
no age restriction or stage of cancer restriction for 
patient inclusion. Data were extracted by two authors 
working independently and using pre-defined outcome 
measures.
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RESULTS
Quantitative data (prevalence) were extracted and 
analysed according to meta-analytical techniques using 
comprehensive meta-analysis. Qualitative data (LR, DR, 
DFS and OS) were presented as ranges. The overall 
proportion of poor responders after neo-adjuvant chemo-
radiotherapy (CRT) was 37.7% (95%CI: 30.1-45.8). 
There were 19 different reported histopathological scales 
and one MRI regression scale (mrTRG). Clinical studies 
used nine and six histopathological scales for poor and 
good responders, respectively. All studies using MRI 
to define good and poor response used one scale. The 
most common histopathological definition for good 
response was the Mandard grades 1 and 2 or Dworak 
grades 3 and 4; Mandard 3, 4 and 5 and Dworak 0, 1 
and 2 were used for poor response. For histopathological 
grades, the 5-year outcomes for poor responders were 
LR 3.4%-4.3%, DR 14.3%-20.3%, DFS 61.7%-68.1% 
and OS 60.7-69.1. Good pathological response 5-year 
outcomes were LR 0%-1.8%, DR 0%-11.6%, DFS 
78.4%-86.7%, and OS 77.4%-88.2%. A poor response 
on MRI (mrTRG 4,5) resulted in 5-year LR 4%-29%, 
DR 9%, DFS 31%-59% and OS 27%-68%. The 5-year 
outcomes with a good response on MRI (mrTRG 1,2 and 
3) were LR 1%-14%, DR 3%, DFS 64%-83% and OS 
72%-90%.
CONCLUSION
For histopathology regression assessment, Mandard 1, 
2/Dworak 3, 4 should be used for good response and 
Mandard 3, 4, 5/Dworak 0, 1, 2 for poor response. MRI 
indicates good and poor response by mrTRG1-3 and 
mrTRG4-5, respectively. 
Key words: Tumour regression; mrTRG; Poor response; 
Neo-adjuvant therapy; Rectal cancer
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The degree of primary tumour regression 
following neo-adjuvant therapy identified on final 
histopathological specimens is a prognostic factor and 
response variation has allowed risk stratification, aiding 
in post-surgical treatment and follow-up decisions. 
To do this effectively, we need to have a common 
language for defining good and poor response. 
Definitions of response using histopathology scales are 
heterogenous with 19 different scales. There is one 
pre-operative magnetic resonance imaging (MRI) scale. 
Outcomes of recurrence and survival histopathology 
regression assessments should use Mandard 1, 2/
Dworak 3, 4 for good response and Mandard 3, 4, 
5/Dworak 0, 1, 2 for poor response. MRI indicates 
good and poor response by mrTRG1-3 and mrTRG4-5, 
respectively.
Siddiqui MRS, Bhoday J, Battersby NJ, Chand M, West 
NP, Abulafi AM, Tekkis PP, Brown G. Defining response to 
radiotherapy in rectal cancer using magnetic resonance imaging 
and histopathological scales. World J Gastroenterol 2016; 
22(37): 8414-8434  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v22/i37/8414.htm  DOI: http://dx.doi.
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INTRODUCTION
Rationale
The multidisciplinary treatment of rectal cancer has 
markedly improved and led to better patient outcomes 
over the last three decades[1]. The reasons for this are 
multifactorial, but one important factor is the use of 
neo-adjuvant or adjuvant therapies[2]. 
The degree of primary tumour regression following 
neo-adjuvant therapy, identified on final histopathological 
specimens, has been shown to be a prognostic factor[3,4]. 
The variation in response allows clinicians to risk-
stratify patients after surgery, which may help in post-
operative decisions, such as who to treat with adjuvant 
chemotherapy and the intensity of follow-up. 
Clinical studies use a number of different tumour 
regression grade (pTRG) scales to classify the degree of 
tumour response to neo-adjuvant chemo-radiotherapy 
(CRT). This often results in confusion as to whether 
a good or poor response has been achieved, with 
subsequent uncertainty regarding treatment and 
prognostic implications. This problem was highlighted 
by MacGregor et al[1] who stressed the importance of a 
universally accepted standard. 
There has been no review of the reported pTRG 
scales to date. It is necessary to highlight the hete-
rogeneity in these scales, in order to consolidate the 
current definitions with the purpose of converging 
towards a set of consensus definitions.
A newer method of assessing tumour regression 
relies on MRI (mrTRG), which has been validated as 
a prognostic tool. This may supercede pTRG, as it has 
the advantage of assessing tumour response before 
surgery. As such, it has the potential for enabling 
response-orientated tailored treatment, including 
alteration of the surgical planes, additional use of 
chemotherapy, or deferral of surgery[5-7]. 
Objective
This article investigates all the pathology tumour 
regression scales used to define good and poor 
response after neo-adjuvant chemotherapy for rectal 
cancer, to establish the true prevalence of poor 
responders and to identify the best scales to use in 
relation to outcomes. 
MATERIALS AND METHODS
Protocol and registration
The title, methods and outcome measures were 
stipulated in advance and the protocol is available in 
the PROSPERO database[8].
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Types of studies
All clinical, histopathological and imaging studies that 
define or attempt to define good and poor responders 
after neo-adjuvant therapy for colorectal cancers were 
identified. Included studies were those investigating 
rectal cancer response to neo-adjuvant therapy in-
corporating chemotherapy, radiotherapy or chemo-
radiotherapy with different protocols. All clinical studies 
were chosen that defined good and poor response in 
relation to TRG or degree of response according to 
histopathology using terms such as “poor response”, 
“minor response”, “less response”, “good response”, 
“major response” or “more response”. 
Types of participants
All rectal cancer patients treated with long course 
radiotherapy or an interval period to surgery were 
selected for this review. All sensitizing chemotherapy 
protocols were included. Any surgical resection was 
included. Studies were also included with any post-
operative adjuvant practice.
Exclusion criteria
Excluded studies were those that did not specifically 
state whether a response was good or poor, or that 
qualify it with some form of inference in the paper. 
Further exclusions were for: non-conventional 
deliveries of neo-adjuvant therapy, such as endo-rectal 
brachytherapy; trans-anal endoscopic microsurgery 
(commonly known as TEMS) and local excisions; and, 
when the reporting scale was in obvious contradiction 
with the order given in the original studies[9].
Types of variable of interest
The original papers reporting the various pTRG scales 
were identified and articles that used the scales in 
clinical, pathological and MRI studies were used in the 
current study. 
Hypotheses and types of outcome measures
The primary hypothesis was that there is an optimal 
histopathological TRG scale that appropriately dis-
tinguishes between good and poor response. The 
secondary hypothesis was that the mrTRG scale dif-
ferentiates between good and poor response. This 
was investigated by first reviewing the clinical studies 
examining the response of rectal cancer to neo-
adjuvant therapy. These studies were used to show 
the range of definitions of good and poor response 
according to histopathology and MRI. This was then 
utilised to identify the optimal scale for identifying 
good and poor response after neo-adjuvant therapy 
for rectal cancer based on recurrence and survival 
outcomes. 
Information sources 
The Cochrane library, CENTRAL, EMBASE, CINAHL and 
PubMed databases were searched between January 
1935 and December 2015. Relevant articles referenced 
in these publications were obtained and the “related 
article” function was used to widen the results. This was 
complemented by hand searches and cross-references 
from papers identified during the initial search. No 
language restriction was applied. 
Searches
The text words “preoperative”, “neo-adjuvant”, “tumour 
regression”, “poor responder”, “good responder”, 
“regression grading”, “regression grade” and “rectal 
cancer” were used in combination with the medical 
subject headings “adjuvant combined modality 
therapy” and “rectal cancer”. Irrelevant articles not 
fulfilling the inclusion criteria were excluded. 
Study selection and data collection process
Each included article according to our review criteria 
was reviewed by two researchers (MRSS and JB). 
Where more specific data or missing data was required, 
the authors of the manuscripts were contacted. 
Data was entered onto an Excel worksheet and 
compared between authors. Any disagreements that 
arose between the reviewers were resolved through 
discussion, and if no consensus could be reached a third 
author (GB) would decide.
Data items
Data were extracted that related to the definition of 
good and poor response according to the TRG scales 
reported in clinical, histopathological and imaging 
studies. The ranges of permutations of each TRG scale 
to define good or poor response were also documented 
and the most commonly used definitions identified. 
The primary hypothesis was proven by examining all of 
the studies on response to neo-adjuvant therapy and 
there is a single definition (which may include other 
scales) that consistently differentiates between good 
and poor responses as defined by local recurrence (LR), 
distant recurrence (DR), disease-free survival (DFS) 
and overall survival (OS).
Risk of bias and quality assessment
Quality assessment and risk of bias was not formally 
assessed due to the exploratory nature of this 
review. Validity of other studies was benchmarked 
to studies that identified a significant difference. 
Clinical heterogeneity can be seen in the table of 
characteristics presented as Table 1.
Summary measures and data synthesis for summative 
and comparative meta-analyses
As part of assessing overall prevalence of poor res-
ponders, cumulative meta-analytical techniques were 
used. Analyses were performed using Comprehensive 
Meta-Analysis 2006 (Version 2, Biostat, Englewood, 
NJ, United States) for Windows 10[10]. In a sensitivity 
analysis, 0.5 was added to each cell frequency for 
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reported 25 definitions for poor response in accordance 
with the TRG[13-33]. Of these, 16 articles also defined 
good response. Table 1 shows the characteristics of 
individual studies.
Qualitative and quantitative syntheses
Histopathological methods of classifying regres­
sion: There were 19 TRG scales reported across 
the studies[18,25,34-51] (Table 2). Only one TRG system 
incorporated whether a response was poor or good[36] 
and used a categorical TRG scale based on the one 
described by Dworak et al[35].
Which scales are used to define poor response using 
histopathological methods?
From the search, nine scales[18,25,34-36,38,40,43,44,46] 
were used in 25 reports (21 articles) to define poor 
response[13-33]. From these 25 reports, the nine scales 
were used in different combinations to produce 16 
individual definitions of poor response (Table 3). 
trials in which no event occurred, according to the 
method recommended by Deeks et al[11] and was not 
considered to affect the overall result necessitating 
the Peto method[12]. Where only a single patient was 
present in any of the groups, this was excluded due to 
the excessive effect of zero cell correction. Outcomes 
were reported as event rates. Forest plots were used for 
the graphical display.
Publication bias
For the outcome of prevalence, publication bias was 
assessed using funnel plots. We used the plots to 
subjectively assess asymmetry and conducted an 
Egger test for quantitative assessment.
RESULTS
Study selection and characteristics
There were 328 references. Full texts of 85 papers were 
reviewed. Overall, 21 articles were of relevance and 
Table 1  Characteristics of studies reporting on good or poor response based upon histopathology
Ref. Year Chemotherapy protocol 
with radiotherapy
Radiotherapy 
protocol (Gy)
Surgical 
procedures
TME Time to 
surgery (wk)
Cancer stage pre 
neo-adjuvant 
therapy
Adjuvant 
therapy
Gambacorta et al[21] 2004 Ralitrexed 50.4 APR/AR/Col-
Anal resection/
Stoma
Y 6-8 Stage 2 or 3 Y
Pucciarelli et al[28] 2004 Fluorouracil, leucovorin 
carboplatin, oxaliplatin
45-50.4 APR/AR/
Hartmann’s
Y 2-8 T2/3/4, N0/1/2 Y
Beddy et al[17] 2008 Fluorouracil 45-50 APR/AR Y T3/4, N1/2
Giralt et al[22] 2008 Tegafir uracil, 
leucovorin
45 + 9 boost APR/AR Y 4-6 T3/4, N0/1/2 Y
Horisberger et al[24] 2008 Capecitabine, irinotecan 50.4 APR/AR/stoma Y 4-7 T2/3/4, N+
Suárez et al[31] 2008 Fluoropyridine-based 50.4 APR/AR/
Hartmann’s
Y 6 Stage 2 or 3 Y
Bujko et al[18] 2010 Fluorouracil, leucovorin 50.4 APR/AR/
Hartmann’s
Y 4-6 Stage 2 or 3 Y
Avallone et al[13] 2011 Fluorouracil, levo-
folinic acid, ralitrexed, 
oxaliplatin
45.0 APR/AR/Stoma Y < 8 T3/4, N0/1/2 Y
Eich et al[19] 2011 Fluorouracil 50.4 APR/AR/TEMS/
Intersphincteric 
Surgery
Y 4-6 Stage 1,2 or 3 Y
Min et al[27] 2011 Fluorouracil, leucovorin 50.4 APR/AR Y 6 T3/4, N0/1/2
Shin et al[30] 2011 Fluorouracil 25-50.4 APR/AR/Pan 4-6 T3/4
Huebner et al[25] 2012 Fluorouracil APR/AR T1/2/3/4, N0/1/2 Y
Lim et al[26] 2012 Capecitabine, 
fluorouracil, leucovorin
44-46+4.6 
boost
Radical 
Proctectomy
Y T3/4, N+ Y
Roy et al[29] 2012 Capecitabine, 
fluorouracil
45-50 Y 4-6 T1/2/3/4, N0/1/2 Y
Vallböhmer et al[32] 2012 Fluorouracil 50.4 APR/AR Y T3/4, N0/1/2
Winkler et al[33] 2012 Capecitabine, oxaliplatin 45-50.4 Y 4-6 Stage 2 or 3 Y
Elezkurtaj et al[20] 2013 Fluorouracil 50.4 Y 4-6
Hermanek et al[23] 2013 APR/AR/
Hartmann’s
Y Y
Fokas et al[14] 2014 Fluorouracil 50.4 APR/AR Y 4-6 T3/4 or any T and 
N+
Y
Santos et al[16] 2014 Fluorouracil 50.4 APR/AR Y < 8 T2N+ or T3/4 Y
Hav et al[15] 2015 Fluorouracil, cetuximab, 
oxaliplatin
25-45 AR/Hartmann’s Y 6-8 T3/4 or any T and 
N+
APR: Abdominoperineal resection; AR: Anterior resection; Pan: Panproctocolectomy; Col-Anal: Colorectal and anal resection; TME: Total mesorectal 
excision; Gy: Gray.
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Table 2  Summary of histopathological tumour regression 
grade scales available in the literature for rectal cancer after 
neo-adjuvant treatment
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TRG scale Mandard
(Low no. - More regression)[43]
   0
   1 Complete regression - absence of residual cancer and 
fibrosis
   2 Presence of rare residual cancer
   3 An increase in the number of residual cancer cells, but 
predominantly fibrosis
   4 Residual cancer outgrowing fibrosis
   5 Absence of regressive changes
TRG scale Modified Mandard (Ryan)
(Low no. - More regression)[37]
   0
   1 TRG 1 and 2 of the Mandard scale
   2 TRG 3 of the Mandard scale
   3 TRG 4 and 5 of the Mandard scale
   4
   5
TRG scale Werner and Hoffler
(Low no. - More regression)[41]
   0
   1 0% viable tumour cells
   2 < 10% viable tumour cells
   3 10%-50% viable tumour cells
   4 > 50% viable tumour cells
   5 No regression
TRG scale Dworak
(Low no. - Less regression)[35]
   0 No regression
   1 Dominant tumour mass with obvious 
fibrosis and/or vasculopathy
   2 Dominant fibrotic change with few
tumour cells or groups(easy to find)
   3 Very few tumour cells in fibrotic tissue with or without 
mucous substance
   4 No tumour cells, only fibrotic mass (total regression or 
response)
   5
TRG scale Modified Dworak
(Low no. - Less regression)[38]
   0 No regression
   1 Regression ≤ 25% of tumour mass (dominant tumour 
mass with obvious fibrosis and/or vasculopathy)
   2 Regression > 25%-50% of tumour mass (dominantly 
fibrotic changes with few tumour cells of groups, easy to 
find)
   3 Regression > 50% of tumour mass (very few tumour 
cells in fibrotic tissue with or without mucous substance)
   4 Complete (total) regression (or response): no vital 
tumour cells
   5
TRG scale AJCC 7th Edition[48]
   0 Complete-no viable cells present
   1 Moderate-single cells/small groups of cancer cells
   2 Minimal-residual cancer outgrown by fibrosis
   3 Poor-minimal or no tumour kill, extensive residual 
cancer
   4
   5
TRG scale Memorial Sloan-Kettering (Low no. - Less regression)[47]
   0 0%-85% regression
   1 86-99% regression
   2 100% regression
   3
   4
   5
TRG scale Cologne
(Low no. - Less regression)[40]
   0
   1 > 50 % Viable rectal tumour cells
   2 10%-50% Viable rectal tumour cells
   3 Near complete regression with < 10% Viable rectal 
tumour cells
   4 Complete regression (pathologic complete remission and 
ypT0)
TRG scale Bujko/Glynne Jones
(Low no. - More regression)[18,44] 
   0 No cancer cells
   1 A few cancer foci in less than 10% of tumour mass
   2 Cancer seen in 10%-50% of tumour mass
   3 Cancer cells seen in more than 50% of tumour mass
   4
TRG scale College of American Pathologists[50]
   0 Complete response: No residual tumour
   1 Marked response: Minimal residual cancer
   2 Moderate response: Residual cancer outgrown by 
fibrosis
   3 Poor or no response: Minimal or no tumour kill; 
extensive residual cancer
   4
TRG scale RCPath system
(Low no. - More regression)[42]
   0
   1 No residual cells and/or mucus lakes only
   2 Minimal residual tumour i.e., microscopic residual 
tumour foci only
   3 No marked regression
   4
TRG scale RCRG system
(Low no. - More regression)[34]
   0
   1 Sterilisation or only microscopic foci of adenocarcinoma 
with marked fibrosis
   2 Marked fibrosis but macroscopic
disease present
   3 Little or no fibrosis with abundant macroscopic disease
   4
TRG scale Mod RCRG system
(Low no. - More regression)[45]
   0
   1 Macroscopic features may be varied. Microscopy reveals 
no tumour or < 5% of area of abnormality
   2 Macroscopic features may be varied. Microscopy reveals 
combination of viable tumour and fibrosis. Tumour 
comprises 5%-50% of overall area of abnormality
   3 Macroscopic or microscopic features may not be 
significantly different. Over 50% comprises tumour. 
Some fibrosis may be present but no more than 
untreated cases
   4
TRG scale Japanese
(Low no. - Less regression)[25] 
   0 No regression
   1a Minimal effect (necrosis less than 1/3)
   1b Mild effect (necrosis less than 2/3 but more than 1/3)
   2 Moderate effect (necrosis more than 2/3 of the lesion)
   3 No tumour cells
TRG scale Ruo
(Low no. - Less regression)[39]
   0 No evidence of response
   1 1% to 33% response
   2 34% to 66% response
   3a 67% to 95% response
   3b 96% to 99% response
   4 100% response (no viable tumour identified)
TRG scale Junker and Muller
(Low no. - Less regression)[46] 
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The overall proportion of poor responders after neo-
adjuvant CRT was 37.7% (95%CI: 30.1-45.8) (Table 
4, Figure 1). Study characteristics can be seen in 
Table 1. Table 5 shows the scales that define poor 
response with their permutations. Most studies used 
the Mandard or Dworak TRG scales. The studies using 
the Mandard scale[13,16,21,22,28-31] defined poor response 
as Mandard TRG 3 to 5, 4 or 4 to 5. The Dworak scale 
uses a similar numerical scale in the opposite direction 
to the Mandard system. From the articles that use the 
Dworak classification for their definitions[14-16,20,25,26,29,33], 
a poor response was defined as Dworak 0 to 1, 1, 1 to 
2 or 0 to 2. 
Outcomes of poor response defined by histopathological 
scales 
Fourteen studies that defined poor response reported 
on outcomes (Table 5). LR at 5 years ranged from 2% 
to 26%[17,18,23,26,27,31], DR was 14.3% to 47%[18,23,26,27,31]. 
One study reported 10-year LR and DR of 3.6% and 
39.6%, respectively[14]. Two-year DFS was 60.3% to 
83.6%[19,29,31], 3-year DFS was 72.6% to 73.8%[30,31], 
4-year DFS was reported by a single study as 47%[18], 
5-year DFS was reported as 56% to 71%[13,16,17,23,26], 
and 10-year DFS was documented as 63%[14]. OS at 
2 years was 87.3% to 92.6%[29] and at 5 years was 
60.7% to 75.8%[16,23,26].
Which scales are used to define good response?
Six scales[18,25,35,40,43,44,46] were used in 20 reports (16 
articles) to define good response[13-16,18,20,21,24-26,28-33]. 
These six scales produced 12 different definitions of 
good response (Table 2). The characteristics of these 
studies are shown in Table 1. Table 6 shows the scales 
defining good response along with their permutations. 
Outcomes of good response defined by pathological 
scales 
Ten studies reported on outcomes (Table 6). Most 
studies defined good response as Mandard 1 to 2, 
1 to 3, 2 to 3 or Dworak 2 to 4, 3 to 4 or 2 to 3. 
LR at 5 years after a good response ranged from 
0% to 9%[16,18,26,31] and DR was reported as 0% to 
34%[16,18,26,31]. One study reported 10-year LR and DR 
of 8.0% and 29.3%, respectively[14]. Two-year DFS 
was 86.1% to 91.7%[29], 3-year DFS was 74.1%[30], 
4-year DFS was 67%[18], 5-year DFS was 78.4% to > 
90%[13,16,26], and 10-year DFS was 73.6%[14]. OS at 2 
years was 89.2% to 92.2%[29], and at 5 years OS was 
   1 No regression
   2a > 10% residual tumour cells
   2b < 10% residual tumour cells
   3 Total regression (no viable tumour cells)
TRG scale Rodel
(Low no. - Less regression)[36] 
   Poor TRG 1 and 0 of the Dworak scale
   Intermediate TRG 2 and 3 of the Dworak scale
   Complete TRG 4 of the Dworak scale
TRG scale Four point scale
Swellengrebel et al[49]
   pCR Pathological complete response without residual 
primary tumour
   Near pCR Isolated residual tumour cells/small groups of residual 
tumour cells
   Response Stromal fibrosis outgrowing
tumour
   No response No regression or those with stromal fibrosis outgrown 
by tumour
TRG scale Modified Mandard TRGN by Dhadda et al[51] 
   TRGN 1 Complete regression with absence of residual cancer and 
fibrosis extending through the wall
   TRGN 2 Presence of rare residual cancer cells scattered through 
the fibrosis
   TRGN 3 An increased number of residual cancer cells, but fibrosis 
is still predominant
Table 3  Permutations of regression scales to define poor and 
good response
Poor response Good response
TRG grading 
system
Studies that used 
the scale
TRG grading 
system
Studies that used 
the scale
Mandard TRG 
3,4,5
Suárez et al[31] Mandard TRG 1,2 Suárez et al[31] 
Santos et al[16] Gambacorta et 
al[21]
Santos et al[16] 
Mandard TRG 4 Gambacorta et 
al[21] 
Mandard TRG 2,3 Avallone et al[13] 
Giralt et al[22] 
Mandard TRG 
4,5
Avallone et al[13] Mandard TRG 
1,2,3
Roy et al[29]
Roy et al[29] Pucciarelli et al[28]
Pucciarelli et al[28] Shin et al[30] 
Shin et al[30]
Dworak 1 Winkler et al[33] Dworak TRG 
2,3,4
Huebner et al[25] 
Roy et al[29] 
Dworak TRG 0,1 Huebner et al[25] Dworak TRG 2,3 Fokas et al[14]
Roy et al[29] 
Fokas et al[14] 
Dworak TRG 1,2 Lim et al[26] Dworak TRG 3,4 Lim et al[26] 
Elezkurtaj et al[20] 
Santos et al[16] 
Hav et al[15]
Dworak TRG 
0,1,2
Elezkurtaj et al[20] Dworak TRG 3 Winkler et al[33] 
Hav et al[15] 
Santos et al[16] 
Rodel TRG 3 
[Dworak 0,1]
Min et al[27] Japanese TRG 2,3 Horisberger et 
al[24]
Rodel TRG 3 
[Wittekind (mod 
Dworak 0,1)]
Hermanek et al[23] Japanese TRG 3 Vallböhmer et 
al[32] 
Japanese TRG 
0,1a,1b
Horisberger et 
al[24] 
 Miller Junker 
TRG 2a and 2b
Vallböhmer et 
al[32]
Japanese TRG 1 Vallböhmer et 
al[32] 
Cologne TRG 3 
and 4
Vallböhmer et 
al[32] 
 Miller Junker 
TRG 1
Vallböhmer et 
al[32] 
Glynne Jones 
TRG 1
Bujko et al[18] 
Miller Junker 
TRG 1,2a
Eich et al[19] 
Cologne TRG 1,2 Vallböhmer et 
al[32] 
Glynne Jones 
TRG 3
Bujko et al[18] 
Wheeler RCRG 
TRG 2
Beddy et al[17] 
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77.4% to 88.2%[16,26].
Considerations and comparison between good and poor 
responders 
A range of survival outcomes existed for good and 
poor response (Table 7). There were 15 reports (11 
articles) comparing outcomes from good and poor 
response[13-16,18,26,28-32]. Four outcome measures were 
examined in detail: LR, DR, DFS and OS.
Studies differentiating between good and poor 
responders for LR
Six reports from five studies[14,16,18,26,31] compared good 
and poor response in relation to LR (Figure 2). Of these, 
one study reported a non-significantly higher LR in 
good responders compared with poor responders[14]. 
Five reports[16,18,26,31] showed LR was higher in poor 
responders, of which only one study showed a 
significant difference[26]. Using the definition given by 
Lim et al[26] there were three other studies with similar 
definitions[16,31]. The reported LR for good response 
ranged from 0% to 1.8%[16,26,31]. There were no studies 
that agreed with Lim et al[26] for the definition of poor 
response. Three studies[16,31] agreed with each other for 
poor response and reported LR of 3.4% to 4.3%. Lim 
et al[26] (which showed a significant difference between 
good and poor) gave LR rate in poor responders of 9.5%. 
This indicates that either Mandard 1 to 2 or Dworak 3 
to 4 should be used to define good response for LR and 
Mandard 3 to 5 or Dworak 0 to 2 or 1 to 2 should be 
Table 4  Proportion of poor responders in the literature according to regression grades
TRG grading system No. of reports (total 25 
reports from 21 studies)
Proportion of poor 
responders
Lower limit of 
confidence Interval
Upper limit of 
confidence Interval
Mandard 8 34.9 22.8 49.4
Dworak 8 47.4 32.5 62.7
Junker/Muller 2 50.8 28.8 72.5
Japanese 2 35.0 20.4 52.9
Wheeler 1 38.9 30.8 47.7
Bujko/Glynne-Jones 1 22.1 15.8 30.0
Rodel based on Dworak 1 52.2 44.9 59.5
Rodel based on Wittekind (modified Dworak) 1 14.7 10.6 19.9
Cologne 1   7.1   3.2 14.8
Study name Event rate and 95%CI
Event rate Lower limit Upper limit
Hav et al  2015 (Dw) 0.632 0.518 0.732
Fokas et al  2014 (Dw) 0.223 0.184 0.266
Santos et al  2014 (Dw) 0.612 0.528 0.689
Santos et al  2014 (Man) 0.496 0.414 0.579
Elezkurtaj et al  2013 (Dw) 0.667 0.570 0.751
Hermanek et al  2013 (Ro-W) 0.147 0.106 0.199
Vallbohmer et al  2012 (Jap) 0.271 0.187 0.374
Vallbohmer et al  2012 (Col) 0.071 0.032 0.148
Vallbohmer et al  2012 (J/M) 0.624 0.516 0.720
Lim et al  2012 (Dw) 0.614 0.574 0.653
Huebner et al  2012 (Dw) 0.257 0.206 0.317
Roy et al  2012 (Dw) 0.560 0.447 0.668
Roy et al  2012 (Man) 0.320 0.225 0.433
Winkler et al  2012 (Dw) 0.273 0.148 0.447
Shin et al  2011 (Man) 0.490 0.395 0.586
Min et al  2011 (Ro-Dw) 0.522 0.449 0.595
Avallone et al  2011 (Man) 0.143 0.076 0.252
Eich et al  2011 (J/M) 0.389 0.284 0.505
Bujko et al  2010 (Bj/GJ) 0.221 0.158 0.300
Beddy et al  2008 (Wh) 0.389 0.308 0.477
Giralt et al  2008 (Man) 0.103 0.050 0.201
Horisberger et al  2008 (Jap) 0.441 0.320 0.568
Suarez et al  2008 (Man) 0.697 0.609 0.773
Pucciarelli et al  2004 (Man) 0.491 0.397 0.585
Gambacorta et al  2004 (Man) 0.185 0.103 0.311
0.377 0.301 0.458
-1.00                   -0.50                  0.00                    0.50                   1.00
                                  Proportion of poor responders
Figure 1  Proportion of patients who responded poorly to neo-adjuvant therapy.
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Table 5  Study definitions of poor response according to histopathological tumour regression grade scales
Ref. Year TRG scale used (original 
disease application)
Are the 
scales 
reported 
accurately?
Poor response 
definition
Total 
(n )
Poor 
responders 
(n )
Average 
F/up in 
months
LR 
(%) 
5 yr
DR 
(%) 
5 yr
DFS (%) OS (%)
Gambacorta et 
al[21]
2004 Mandard (oesophagus) Yes TRG 4   54   10   25
Pucciarelli et 
al[28]
2004 Mandard (oesophagus) Yes TRG 4 and 5 106   52   42
Beddy et al[17] 2008 Wheeler (rectal) Yes TRG 2 126   49   37 21 Yr. 5: 71
Giralt et al[22] 2008 Mandard (oesophagus) No TRG 4   68     7
Horisberger et 
al[24]
2008 Japanese Society for 
Cancer of the Colon and 
Rectum (rectal)
Yes TRG 0 and 1a and 
1b
  59   26
Suárez et al[31] 2008 Mandard (oesophagus) Yes TRG 3 and 4 and 5 119   83   33 3.41 14.31 Yr. 2: 83.6
Yr. 3: 73.8
Bujko et al[18] 2010 Glynne Jones/Bujko 
(rectal)
Yes TRG 3 131   29   48 26 47 Yr. 4: 47
Avallone et 
al[13]
2011 Mandard (oesophagus) Yes TRG 4 and 5   63     9   60 Yr. 5: Prob free 
of recurrence 
562
Eich et al[19] 2011 Müller and Junker 
(lung)
Yes TRG 1 and 2a   72   28   28 Yr. 2: 76 ± 14.8
Min et al[27] 2011 Rodel (rectal based on 
Dworak)
Yes Categorised as poor 
according to Rodel 
and based on TRG 
0 and 1 on Dworak 
scale
178   93   43 21 31
Shin et al[30] 2011 Mandard (oesophagus) Yes TRG 4 and 5 102   50      40.3 Yr. 3: 72.6
Huebner et 
al[25]
2012 Dworak (rectal) Yes TRG 0+1 237   61
Lim et al[26] 2012 Dworak (rectal) Yes TRG 1+2 581 357   61 9.5 27.2 Yr. 5: 63.6 Yr. 5: 71.3
Roy et al[29] 2012 Dworak (rectal) Yes TRG 0 and 1   75   42 Yr. 2: 68.9 Yr. 2: 92.6
Roy et al[29] 2012 Mandard (oesophagus) Yes TRG 4 and 5   75   24 Yr. 2: 60.3 Yr. 2: 87.3
Vallböhmer et 
al[32]
2012 Japanese Society for 
Cancer of the Colon and 
Rectum (rectal)
Yes TRG 1   85   23
Vallböhmer et 
al[32]
2012 Junker Miller (lung) Yes TRG 1   85     6 DNE
Vallböhmer et 
al[32]
2012 Cologne (oesophageal) Yes TRG 1 and 2   85   53 DNE
Winkler et al[33] 2012 Dworak (rectal) No TRG 1   33     9 DNE
Elezkurtaj et 
al[20]
2013 Dworak (rectal) Yes TRG 0,1 and 2 102   68
Hermanek et 
al[23]
2013 Rodel (rectal based 
on Wittekind and 
Tannapfel (rectal based 
on Dworak)
Yes Categorised as poor 
according to Rodel 
and based on TRG 
0and1 on Wittekind 
and Tannapfel (a 
modified Dworak 
scale)
225   33   92 15.9 27.9 Yr. 5: 63.6 Yr. 5: 75.8
Fokas et al[14] 2014 Dworak (rectal) Yes TRG 0+1 386   90 132 Yr. 
10: 
3.6
Yr. 10: 
39.6
Yr. 10: 63%
Santos et al[16] 2014 Dworak (rectal) Yes TRG 0,1 and 2 144   85   56 3.5 16.4 Yr. 5: 68.1 Yr. 5: 69.1
Santos et al[16] 2014 Mandard (oesophagus) Yes TRG 3 and 4 and 5 144   69   56 4.3 20.3 Yr. 5: 61.7 Yr. 5: 60.7
Hav et al[15] 2015 Dworak (rectal) Yes TRG 0,1 and 2   76   48   20 No specific 
data but no 
correlation 
with DFS
1Overall rate for total follow-up time; 2Probability of being free from recurrence (DFS rate not given). LR: Local recurrence; DR: Distant recurrence.
Siddiqui MRS et al . Defining good and poor response after neo-adjuvant therapy
8422 October 7, 2016|Volume 22|Issue 37|WJG|www.wjgnet.com
used for poor response. 
Studies differentiating between good and poor response 
for DR
Six reports from five studies[14,16,18,26,31] compared good 
and poor response in relation to DR (Figure 3). Of 
these, all showed DR was higher in poor responders, 
of which two studies (Lim et al[26] and Fokas et al[14]) 
showed a significant difference; although, they used 
different definitions. Using the definition given by Lim 
et al[26], there were three other studies with similar 
definitions[16,31]; the reported 5-year DR for good 
response was 0% to 11.6%. Using the definition given 
by Fokas et al[14], there was one other study with a 
similar definition[18]; the reported 5- and 10-year DR 
for good response was 34% and 29%, respectively. 
Poor response was defined by three studies[16,31], with 
similar definitions reporting DR of 14.3% to 20.3%. 
Poor response was 47% and 39.6% for 5- and 10-year 
DR, respectively, by two other studies[14,18] with similar 
Table 6  Study definitions of good response according to histopathological tumour regression grade scales
Ref. Year TRG scale 
used (original 
disease 
application)
Are the 
scales 
reported 
accurately?
Good 
response 
definition
Total 
(n )
Good 
responders 
(n )
Average 
F/up in 
months
LR 
(%) 
5 yr
DR 
(%) 
5 yr
DFS (%) OS (%)
Gambacorta et al[21] 2004 Mandard 
(oesophagus)
Yes TRG 1 and 2 54   24   25
Pucciarelli et al[28] 2004 Mandard 
(oesophagus)
Yes TRG 1 and 2 
and 3 
104   52   42 DNE DNE
Horisberger et al[24] 2008 Japanese 
Society for 
Cancer of the 
Colon and 
Rectum (rectal)
Yes TRG 2 and 3   59   33
Suárez et al[31] 2008 Mandard 
(oesophagus)
Yes TRG 1 and 2 119   36   33 0   0 DNE
Bujko et al[18] 2010 Glynne Jones/
Bujko (rectal)
Yes TRG 1 131   40   48 9 34 Yr. 4: 67
Avallone et al[13] 2011 Mandard 
(oesophagus)
Yes TRG 2 and 3   63   20   60 Yr. 5: Prob free of 
recurrence > 90%
Shin et al[30] 2011 Mandard 
(oesophagus)
Yes TRG 1 and 2 
and 3
102   52      40.3 Yr. 3: 74.1
Huebner et al[25] 2012 Dworak 
(rectal)
Yes TRG 2 and 3 
and 4
237 176
Lim et al[26] 2012 Dworak 
(rectal)
Yes TRG 3 and 4 581 224   61    1.3 11.6 Yr. 5: 86.7 Yr. 5: 88.2
Roy et al[29] 2012 Dworak 
(rectal)
Yes TRG 2 and 3 
and 4
  75   33 Yr. 2: 91.7 Yr. 2: 89.2
Roy et al[29] 2012 Mandard 
(oesophagus)
Yes TRG 1 and 2 
and 3
  75   51 Yr. 2: 86.1 Yr. 2: 92.2
Vallböhmer et al[32] 2012 Japanese 
Society for 
Cancer of the 
Colon and 
Rectum (rectal)
Yes TRG 3   85   23 DNE
Vallböhmer et al[32] 2012 Junker Miller 
(lung)
Yes TRG 2aand2b   85   65 DNE
Vallböhmer et al[32] 2012 Cologne 
(oesophageal)
Yes TRG 3 and 4   85   26 DNE
Winkler et al[33] 2012 Dworak 
(rectal)
No TRG 3   33     6
Elezkurtaj et al[20] 2013 Dworak 
(rectal)
Yes TRG 3 and 4 102   34
Fokas et al[14] 2014 Dworak 
(rectal)
Yes TRG 2 and 3 386 256 132 Yr. 
10: 
8.0
Yr. 
10: 
29.3
Yr. 10: 73.6%
Santos et al[16] 2014 Dworak 
(rectal)
Yes TRG 3 and 4 144   54   56 1.8 11.1 Yr. 5: 78.4 Yr. 5: 77.4
Santos et al[16] 2014 Mandard 
(oesophagus)
Yes TRG 1 and 2 144   70   56 1.4 8.6 Yr. 5: 81.7 Yr. 5: 79.4
Hav et al[15] 2015 Dworak 
(rectal)
Yes TRG 3 and 4   76   28   20 No specific data 
but no correlation 
with DFS
Overall rate for total follow-up time. LR: Local recurrence; DR: Distant recurrence; DNE: Data given but not extractable; DFS: Disease-free survival.
Siddiqui MRS et al . Defining good and poor response after neo-adjuvant therapy
8423 October 7, 2016|Volume 22|Issue 37|WJG|www.wjgnet.com
Table 7  Comparison of outcomes between good and poor responders
Ref. Year Good 
response 
defn.
Poor 
response 
defn.
LR % P < 
0.05
DR % P < 
0.05
DFS % P < 
0.05
OS % P < 
0.05
DSS P  < 
0.05
Conclusion
GR PR GR PR GR PR GR PR GR PR
Pucciarelli 
et al[28] 
2004 TRG 1 
and 2 
and 3
TRG 4 
and 5
Better in 
GR
No Better in 
GR
No Good responders have 
better, non-statistically 
significant outcomes for 
DFS and OS
Suárez et 
al[31] 
2008 TRG 1 
and 2
TRG 3 
and 4 
and 5
0 3.4 NC 0 14.3 NC Better 
in GR
Yes Better in 
GR
No Good responders have 
better, statistically 
significant DFS but have 
better, non significant LR, 
DR and DSS 
Bujko et 
al[18]
2010 TRG 1 TRG 3 9 26 No 34 47 No 67 47 No Good responders have 
better, non-statistically 
significant outcomes for LR, 
DR and DFS
Avallone et 
al[13]
2011 TRG 2 
and 3
TRG 4 
and 5
Prob 
> 90%
Prob 
56%
Yes Good responders have 
better, statistically 
significant DFS
Shin et al[30] 2011 TRG 1 
and 2 
and 3
TRG 4 
and 5
74.1 72.6 No Good responders have 
better, non-statistically 
significant outcomes for 
DFS
Lim et al[26] 2012 TRG 3 
and 4
TRG 1 
and 2
1.3 9.5 Yes 11.6 27.2 Yes 86.7 63.6 Yes 88.2 71.3 Yes Good responders have 
better, statistically 
significant outcomes for LR, 
DR, DFS and OS
Roy et al[29] 2012 TRG 1 
and 2 
and 3
TRG 4 
and 5
86.1 60.3 Yes 92.2 87.3 No Good responders have 
better, statistically 
significant DFS but have 
better, non significant OS
Roy et al[29] 2012 TRG 2 
and 3 
and 4
TRG 0 
and 1
91.7 68.9 No 89.2 92.6 No Good responders had better, 
non-statistically significant 
outcomes for DFS. Good 
responders had poorer, 
non-statistically significant 
outcomes for OS
Vallböhmer 
et al[32]
2012 TRG 3 TRG 1 Better in 
GR
No Good responders have 
better, non-statistically 
significant outcomes for OS
Vallböhmer 
et al[32]
2012 TRG 2a 
and 2b
TRG 1 Better in 
GR
No Good responders have 
better, non-statistically 
significant outcomes for OS
Vallböhmer 
et al[32]
2012 TRG 3 
and 4
TRG 1 
and 2
Better in 
GR
No There was no statistically 
significant difference for 
OS between good and poor 
responders
Fokas et 
al[14]
2014 TRG 2 
and 3
TRG 0 
and 1
8 3.6 No 29.3 39.6 Yes 73.6 63 Yes Good responders have 
better, statistically 
significant outcomes for DR 
and DFS. Good responders 
had poorer, non-statistically 
significant outcomes for LR
Santos et 
al[16]
2014 TRG 1 
and 2
TRG 3 
and 4 
and 5
1.4 4.3 NC 8.6 20.3 NC 81.7 61.7 Yes 79.4 60.7 Yes Good responders have 
better, statistically 
significant outcomes for 
DFS and OS
Santos et 
al[16]
2014 TRG 3 
and 4
TRG 0 
and 1 
and 2
1.8 3.5 NC 11.1 16.4 NC 78.4 68.1 No 77.4 69.1 No Good responders have 
better, non-statistically 
significant outcomes for 
DFS and OS
Hav et al[15] 2015 TRG 3 
and 4
TRG 0 
and 1 
and 2
Better 
in GR
No Good responders have 
better, non-statistically 
significant outcomes for 
DFS
Where data is not given the overall result is stated. LR: Local recurrence; DR: Distant recurrence; GR: Good responders; PR: Poor responders; NC: No 
statistical comparison made.
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definitions. Lim et al[26] reported 5-year DR as 27.2% 
for poor responders. The values reported by Fokas et 
al[14] and Bujko et al[18] are much higher than the other 
reports and do not reflect the body of literature. It 
would, therefore, be preferable to use either Mandard 1 
to 2 or Dworak 3 to 4 for defining good response for DR 
and Mandard 3 to 5 or Dworak 0 to 2 or 1 to 2 for poor 
response. 
Figure 2  Studies reporting on local recurrence in good and poor responders.
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Studies differentiating between good and poor response 
for DFS
Twelve reports[13-16,18,26,28-31] compared good and poor 
response in relation to DFS (Figure 4). All of the 
studies showed DFS to be worse in poor responders. 
Six studies showed a significant difference between 
good and poor response[13,14,16,26,29,31]. For the definition 
of good response, three of the papers[16,26,31] showing a 
statistical significance used a similar definition to each 
other; two[13,14] used different definitions but were 
Figure 3  Studies reporting on distant recurrence in good and poor responders.
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similar to each other and one used a different definition 
to the other significant studies[29]. Using the definition 
given by Lim et al[26] and comparing it to studies with 
similar definitions[15,16,30,31], the reported DFS for good 
response at 5 years was 78.4% to 86.7%. Using the 
definition given by Fokas et al[14] and comparing it 
with the other reports with similar definitions[13], the 
reported 5- and 10-year DFS for good response was 
> 90% and 73.6%, respectively. Using the definition 
by Roy et al[29] and comparing it with the other studies 
with similar definitions[28-30], 2-year DFS was 86.1% to 
91.7% and 3-year DFS was 74.1%.
For the definition of poor response, three of the 
papers[13,14,29] showing a statistical significance used 
a similar definition to each other, two[16,31] used 
different definitions but were similar to each other 
and one study was different in its definition of poor 
response[26]. Using the definition given by Avallone 
et al[13] and comparing it to the other studies with 
similar definitions[14,18,28-30], the reported DFS for poor 
response at 2 years was 60.3% to 68.9%, at 3 years 
was 72.6%, at 4 years was 47%, and at 5 years was 
56%. Using the definition given by Suárez et al[31] 
and comparing it with the other studies with similar 
definitions[15,16], the reported DFS for poor response 
at 2 years was 83.6%, at 3 years was 73.8%, and at 
5 years was 61.7% to 68.1%. Lim et al[26] reports a 
5-year DFS of 63.6%. From these results it may be 
appropriate to use Mandard 1 to 2, 1 to 3 or 2 to 3 
or Dworak 3 to 4, 2 to 4 or 2 to 3 for defining good 
response and Mandard 4 to 5, 3 to 5 or Dworak 0 to 1, 
0 to 2 or Bujko 3 to define poor response.
Studies differentiating between good and poor response 
for OS
Nine reports[16,26,28,29,32] compared good and poor 
response in relation to OS (Figure 5). Of these, all but 
one[29] showed OS was non-significantly worse in poor 
responders. Six reports from four papers showed a 
significant difference[16,28,29,32]. For the definition of good 
response, two of the papers[16,32] showing a statistical 
significance used a similar definition to each other; two 
reports from one paper[32] used different definitions 
but were similar to each other, and a further two used 
similar definitions to each other but were different 
from the other papers[28,29]. Using the definition given 
by Pucciarelli et al[28] and comparing it with the other 
studies with similar definitions[29], the reported OS 
for good response at 2 years was 92.2%. Using the 
definition given by Lim et al[26] and comparing it with 
the other studies with similar definitions[16,26,32], the 
reported OS for good response at 5 years was 77.4% 
to 88.2%.
For the definition of poor response, two of the 
papers[28,29] showing a statistical significance used 
a similar definition to each other and a further two 
studies had similar definitions to each other[16,32]. 
Two reports from one study were different in their 
definitions of poor response[32]. Using the definition 
given by Pucciarelli et al[28] and comparing it with other 
reports with similar definitions[29], the reported OS 
for poor response was 87.3% at 2 years. Using the 
definition given by Vallböhmer et al[32] and comparing it 
with the studies with similar definitions[26], the reported 
OS for poor response was 71.3% at 5 years. Using 
the next definition given by Vallböhmer et al[32] and 
comparing it with studies with similar definitions[16], 
the reported OS for poor response was 60.7% to 
69.1% at 5 years. From these results it may be 
appropriate to use Mandard 1 to 2, 1 to 3 or Dworak 
3 to 4 or Cologne 3 to 4 for defining good response 
and Mandard 4 to 5, 3 to 5 or Dworak 0 to 2, 1 to 2 
or Japanese 1a to 1b or Cologne 1 to 2 to define poor 
response.
Consensus histopathological definition of good and 
poor response 
These results show that across the outcomes of LR, 
DR, DFS and OS, Mandard 1 to 2 and Dworak 3 to 4 
could be used for defining good response and Mandard 
3 to 5 and Dworak 0 to 2 for poor response. 
MRI method of classifying regression
There was one mrTRG system using a 5-point scale[52] 
(Table 8). Lower mrTRG refers to greater regression 
and the system also divides the categories into type 
of response (complete, good, moderate, slight and 
none).
There were five papers on five studies reporting on 
poor response[5-7,52,53]. Characteristics of these studies 
can be seen in Table 9. Overall, the reported proportion 
of poor responders after neo-adjuvant CRT was 38.6% 
(95%CI: 34.5%-42.8%) and there was only moderate 
heterogeneity that was still significant (Q = 10.7, df = 
4, I2 = 63, p = 0.03) (Figure 6). 
Definition of poor response as defined by MRI
Two studies[5-7] stated that mrTRG was based on the 
Dworak scale, but the hierarchy actually follows that 
of the Mandard scale (Table 10). Three studies stated 
that it was based on the Mandard scale[52,53]. Poor 
response was defined as mrTRG 4 and mrTRG 5 by 
all of the papers. LR for poor responders at 5 years 
ranged from 4% to 29%[6,52]. Five year DR was 9%[52]. 
From our centres, unpublished data for 3-year DFS 
was 52%[53] and 5-year DFS was 31% to 68%[6,53]. OS 
at 3 years from this centre was 74%[53] and at 5 years 
was 27% to 68%[6,53].
Outcomes of good response defined by MRI TRG scales 
LR rates for good responders at 5 years ranged from 
1% to 14%[6,52]. Five-year DR was 3%[52] and DFS was 
64% to 83%[6,53]. OS at 5 years was 72% to 90%[6,53] 
(Table 11).
Considerations and comparison between good and poor 
responders 
mrTRG is a relatively new scale and the studies 
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Figure 4  Studies reporting on disease- free survival in good and poor responders.
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reporting it are from one centre; hence, consistency 
would be expected. Good responders were defined 
as mrTRG 1 to 3 or 1 to 2 and poor responders were 
defined as mrTRG 4 to 5 (Table 12).
Studies differentiating between good and poor 
responders for LR, DR, DFS and OS
There are three articles with available data comparing 
outcomes for good and poor responders (Table 11). In 
Figure 5  Studies reporting on overall survival in good and poor responders.
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all three reports, good responders had better outcomes 
compared with poor responders in relation to LR, DR, 
DFS and OS. Furthermore in all but LR there was a 
statistically significant difference in outcomes.
Although there was a range of survival outcomes, 
the overall rates for survival are lower in poor 
responders, distinguishing them clearly from the 
survival figures and rates of those with good response. 
Consensus mrTRG definition of good and poor 
response 
From these results, good response may be defined as 
mrTRG 1 to 3 or 1 to 2 (with mrTRG3 as a separate, 
independent group) and poor responders as mrTRG 4 
to 5. This consistency of results, therefore, indicates 
the secondary hypothesis is likely to be true.
Publication bias for prevalence
Publication bias for prevalence from histology was 
initially assessed using a funnel plot (Figure 7). 
There appeared to be some asymmetry on the plot 
and so Eggers test was used. There was statistically 
significant asymmetry seen (Intercept: -4.30, SE: 2.23, 
95%CI:-8.90-0.31, t = 1.93, p = 0.07), indicating 
there is unlikely to be significant publication bias.
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DISCUSSION
The aim of this review was to investigate the range 
and method of how poor response to neo-adjuvant 
therapy for rectal cancer is defined in order to see 
which scale best distinguishes between the two groups 
in relation to outcomes.
Main findings
In summary, this paper has shown that across the 
outcomes of LR, DR, DFS and OS, Mandard 1, 2 and 
Dworak 3, 4 could be used for defining good response 
and Mandard 3, 4, 5 and Dworak 0, 1, 2 for defining 
poor response. There are other definitions shown 
above which may also differentiate good and poor 
response. The analysis has shown differences in the 
reliability of these scales in consistently identifying 
good and poor responders. 
Summary and appraisal of evidence 
Our results have shown that there are three major 
Study name Event rate and 95%CI
Event rate Lower limit Upper limit
Shihab et al  2011 0.459 0.308 0.619
Patel et al  and Patel et al  2011, 2012 0.319 0.220 0.437
Patel et al  2012 0.515 0.396 0.633
Yu et al  2014 (retrospective) 0.405 0.340 0.472
Yu et al  2014 (prospective) 0.309 0.241 0.387
0.386 0.345 0.428
-1.00    -0.50    0.00     0.50     1.00
            Poor           Responders
Figure 6  Proportion of patients who responded poorly to neo-adjuvant therapy according to magnetic resonance imaging.
Table 8  Summary of magnetic resonance imaging regression 
scale available in the literature
mrTRG scale mrTRG
(Low no. - More regression)[47]
1 Radiological complete response: no evidence of ever 
treated tumour
2 Good response (dense fibrosis; no obvious residual 
tumour, signifying minimal residual disease or no 
tumour)
3 Moderate response (50% fibrosis or mucin, and visible 
intermediate signal)
4 Slight response (little areas of fibrosis or mucin but 
mostly tumour)
5 No response (intermediate signal intensity, same 
appearances as original tumour)
0.0
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-3           -2           -1           0            1            2            3
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Figure 7  Funnel plot for studies reporting on the prevalence of poor 
response according to histology.
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challenges when it comes to the standardization 
of tumour regression for rectal cancer. The first is 
the vast choice of regression scales available to 
histopathologists. The second is that studies use 
these varied scales to define poor response without 
consistency. The third is that there are marked 
differences between the scales. Therefore, trying to 
merge these systems into one, universally acceptable 
Table 9  Characteristics of studies reporting on poor response based upon magnetic resonance imaging
Ref. Year Chemotherapy protocol Radiotherapy 
protocol (Gy)
Surgical 
procedures
TME Time to 
surgery (wk)
Cancer stage 
Pre neo-
adjuvant 
therapy
Adjuvant 
therapy
Shihab et al[52] 2011 APR/AR Y
Patel et al[7] and 
Siddiqui et al[8]
2011 and 2012 APR/AR Y
Patel et al[6] 2012 APR/AR Y T1/2/3/4, 
N0/1/2
Y
Yu[53] 2014 (unpublished data 
from our centre)
Capecitabine, oxaliplatin ± 
cetuximab
50.4-54 Y T2/3/4 Y
Yu[53] 2014 (unpublished data 
from our centre)
Capecitabine, oxaliplatin ± 
cetuximab
50.4-54 Y T2/3/4 Y
Table 10  Study definitions of poor response according to magnetic resonance imaging tumour regression grade scales
Ref. Year TRG scale used 
(histological stage 
based upon)
Scales 
accurate?
Poor 
response 
definition
Total 
(n )
Poor 
responders 
(n )
Average 
F/up in 
months
LR (%) 
5 yr
DR (%) 
5 yr
DFS (%) OS (%)
Shihab et al[52] 2011 MRI TRG (based on 
Mandard)
Yes TRG 4,5 37 17 4 9
Patel et al[5,7] 2012 MRI TRG (based on 
Dworak)
Yes TRG 4,5 69 22
Patel et al[6] and 
Patel et al[7]
2011 and 2012 MRI TRG (based on 
Dworak)
Yes TRG 4,5 66 34 60 29 Yr. 5: 31 Yr. 5: 27
Yu[53] 2014 
(unpublished 
data from our 
centre)
MRI TRG (based 
on Mandard and 
Dworak)
Yes TRG 4,5 210 85 Yr. 3: 52% Yr. 3: 74%
Yu[53] 2014 
(unpublished 
data from our 
centre)
MRI TRG (based 
on Mandard and 
Dworak)
Yes TRG 4,5 152 47 Yr. 5: 59% Yr. 5: 68%
LR: Local recurrence; DR: Distant recurrence; DFS: Disease-free survival; OS: Overall survival; TRG: Tumour regression grade.
Table 11  Study definitions of good response according to magnetic resonance imaging tumour regression grade scales
Ref. Year TRG 
scale used 
(histological 
stage based 
upon)
Scales 
accurate?
Good 
response 
definition
Total 
(n )
Good 
responders (n)
Average 
F/up in 
months
LR (%) 
5 yr
DR (%) 
5 yr
DFS (%) OS (%)
Shihab et al[52] 2011 MRI TRG 
(based on 
Mandard)
Yes TRG 1,2,3 37 20 1 3
Patel et al[6] 2012 MRI TRG 
(based on 
Dworak)
Yes TRG 1,2,3 69 47
Patel et al[5] 
and Patel et 
al[7]
2011 and 2012 MRI TRG 
(based on 
Dworak)
Yes TRG 1,2,3 66 32 60 14 Yr. 5: 64 Yr. 5: 72
Yu[53] 2014 
(unpublished data 
from our centre)
MRI TRG 
(based on 
Mandard and 
Dworak)
Yes TRG 1,2 152 61 DFS, Yr. 5: 
83%
DFS, Yr. 5: 
90%
LR: Local recurrence; DR: Distant recurrence; DFS: Disease- free survival; OS: Overall survival; TRG: Tumour regression grade.
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scale becomes unrealistic. Furthermore, studies 
have shown that inter-observer agreement amongst 
histopathologists using the existing scales is low[54]. 
The scales themselves do not advise on whether 
histopathologists should use a single worst slide for 
assessment or a composite assessment and adds to 
the challenge of defining good and poor response. 
This was highlighted by a study which showed poor 
inter-observer agreement between histopatholo-
gists assessing regression using different regression 
scales[54].
Some of the scales use qualitative estimates[25,39,46] 
for levels of fibrosis, but these overlap with regression 
grades in alternative scales given in other studies[35,43]. 
Even by trying to examine the correlation between two 
systems, two grades may be grouped into one grade 
on a different scale.
Both MRI and histopathological grading systems 
are open for misinterpretation if standard methods 
of preparation and interpretation are not employed; 
there has been a focused attempt to do this in relation 
to histopathological assessment[54,55] and mrTRG is a 
novel scale requiring appropriate training to ensure 
consistency when utilised in other centres.
Differences in the definitions of poor response 
are highlighted by the number of poor responders 
identified in each of the studies (Figures 1 and 6). 
This review concentrated on studies using specific 
terms stating what they believed to be poor response; 
however, there were studies that divided TRG into two 
groups but did not specifically state them as good and 
poor responders; their results are consistent with the 
range that is reported in this paper but differ in that 
they show a good correlation to outcomes for their 
presumed good and poor responders[56]. 
In relation to the original definitions, one study 
showed that poor responders could be either those 
with predominant fibrosis or patients with tumour 
outgrowing fibrosis[31] compared with other studies 
using the same Mandard scale which only defined 
poor responders as those with tumour outgrowing 
fibrosis[22]. This is then compounded by the fact 
that more than one grade on other scales could be 
combined together on an alternative system.
Importance and implications for practice
Historically, the histopathological TRG systems were 
developed without validation of the grading in relation 
to outcomes, and evolution of these scales has 
occurred with the presence of long-term prognostic 
information. Histopathological TRG is also dependent 
on thorough pathological sampling and comparisons 
are not made to the pre-treatment biopsy; therefore, 
high stromal content tumours are often given a better 
regression grade, even though the high stroma may 
not be due to regression. mrTRG may be one way 
to respond to this, as it compares and examines the 
whole tumour and because of the presence of one-
scale heterogeneity is reduced. mrTRG also better 
distinguishes between good and poor response in 
relation to survival. LR appears to be reported with a 
large range using both histopathological and mrTRG 
and may relate to surgical factors being the most 
important issue in relation to this outcome.
Implications for research and further studies
Recent data from our centre would suggest that 
mrTRG3, whilst traditionally considered a good 
response, behaves more like the poor responder 
group[57] and could be considered as a separate 
group[58]. 
In summary, this paper has shown that across 
the outcomes of LR, DR, DFS and OS, Mandard 1 to 
2 and Dworak 3 to 4 could be used for defining good 
Table 12  Comparison of outcomes between good and poor responders
Ref. Year Local 
recurrence 
(LR)
P  < 
0.05
Distant 
recurrence 
(DR)
P  < 
0.05
Progression 
disease-free 
survival (DFS)
P  < 
0.05
Disease-
free 
survival 
(DFS)
P  < 
0.05
Overall 
survival 
(OS)
P  < 
0.05
Conclusion
Shihab et al[52] 2011 Better in GR No Better in GR Yes Good responders have 
better, statistically 
significant outcomes for 
DR but have better, non 
significant LR
Patel et al[5] 
and Patel et 
al[7]
2011 
and 
2012
Better in GR No Better in 
GR
Yes Better in 
GR
Yes Good responders have 
better, statistically 
significant outcomes for 
DFS and OS but have 
better, non significant 
outcomes for LR
Yu[53] 2014 Better in GR Yes Better in 
GR
Yes Good responders have 
better, statistically 
significant outcomes for 
DFS and OS
GR: Good responders; NC: No statistical comparison made; DNI: Data not interpretable.
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response and Mandard 3 to 5 and Dworak 0 to 2 for 
poor response. These definitions may help in achieving 
consensus in histopathological reporting. However, 
these definitions do not always produce a significant 
difference in the outcomes from the different studies 
utilizing these definitions. Furthermore, there are 
other definitions shown above which may also 
differentiate good and poor response. This casts 
doubt on the reliability of these scales in consistently 
identifying good and poor responders. A preoperative 
grading system, such as mrTRG, may be useful to 
appropriately differentiate good and poor response, 
thus guiding management decisions, and images 
attained could effectively be attained by high resolution 
MRI imaging.
A range of histopathological TRG scales is used 
in clinical studies. Good and poor response are 
heterogeneously described, even when using the 
same histopathological regression scales. Across the 
outcomes of LR, DR, DFS and OS, Mandard 1 to 2 
and Dworak 3 to 4 could be used for defining good 
response and Mandard 3 to 5 and Dworak 0 to 2 for 
poor response. These definitions may help in achieving 
consensus in histopathological reporting. Preoperative 
mrTRG is similarly able to differentiate between good 
and poor response based on outcomes.
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